Reports
Sale
Alzheimer’s Drugs Market Size, Share, Analysis, Forecast: By Drug Class: Memantine, Cholinergic, Combined Drug, Others; By Route of Administration: Oral, Parenteral; By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Others; Regional Analysis; Market Dynamics: SWOT Analysis, PESTEL Analysis; Supplier Landscape; 2024-2032
Alzheimer’s Drugs Market Size
The Alzheimer’s drugs market was valued at USD 5.75 billion in 2023, driven by the increasing aging population and rising awareness about Alzheimer's disease and related dementia across the 8 major markets. The market is expected to grow at a CAGR of 7.12% during the forecast period of 2024-2032, with the values likely to reach USD 10.67 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Alzheimer’s Drugs Market Outlook
- As the global population ages, the prevalence of Alzheimer's disease and other forms of dementia continues to rise. This demographic trend contributes to a growing patient population in need of effective treatments, which leads to growth in market demand.
- The ongoing research efforts have led to a deeper understanding of the underlying mechanisms of Alzheimer's disease, including the role of beta-amyloid plaques, tau protein tangles, and neuroinflammation. This knowledge fuels the development of new drug targets and therapeutic approaches, which is acting as great opportunity for market growth.
- There are numerous drugs in various stages of clinical development for Alzheimer's disease. These include monoclonal antibodies targeting beta-amyloid, small molecule inhibitors which are driving the growth of the market.
Alzheimer’s Drugs Market Overview
Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects older adults. It is the most common cause of dementia, accounting for 60-70% of cases. According to an article published by Alzheimer’s A ssociation, an estimated 6.9 million Americans are living with Alzheimer's dementia.
Alzheimer's disease affects millions of people worldwide, with numbers expected to increase significantly as populations age. This demographic shift is a major driver of market growth. Moreover, the market for Alzheimer's drugs is substantial, driven by the high cost of drug development and the potential for significant returns due to the large patient population in need of effective treatments.
Despite availability of treatments, there remains a significant unmet need for therapies that can slow or halt disease progression. This increases the demand for drugs and hence augmenting the market growth. Moreover, the advances in understanding disease mechanisms, biomarker identification, and personalized medicine offer promising avenues for future drug development. Digital health technologies and patient-centric approaches are also expected to play a significant role in shaping the future of Alzheimer's treatments.
Alzheimer’s Drugs Market Growth Drivers
Rising Disease Prevalence
Alzheimer's disease is one of the leading causes of dementia, accounting for a substantial portion of dementia cases globally. The increasing prevalence of Alzheimer's disease, particularly in developed countries where populations are aging rapidly, contributes to the growing demand for effective treatments. The World Health Organization reports that, more than 55 million people have dementia worldwide currently, over 60% of whom, live in low-and middle-income countries.
The rising prevalence of Alzheimer's disease stimulates research and development efforts in the pharmaceutical and biotechnology sectors. Pharmaceutical companies and research institutions are motivated to invest in novel therapeutic approaches, biomarkers, and diagnostic tools aimed at addressing the complex challenges posed by Alzheimer's disease.
Alzheimer's disease imposes a substantial burden on healthcare systems due to its progressive nature and long-term care needs. This burden includes healthcare costs associated with diagnosis, treatment, caregiving, and management of disease-related complications. The economic impact drives investments in research and development of new therapies that can alleviate the market demand.
Growing Geriatric Population is Expected to Propel Alzheimer’s Drugs Market Demand
The primary demographic driver for the Alzheimer's drugs market is the increasing aging population worldwide. Alzheimer's disease predominantly affects older adults, and as life expectancy rises globally, the number of people living with Alzheimer's and other dementias is expected to grow significantly. According to the 2019 World Population Prospects, by 2050, 1 in 6 people in the world will be over age 65, up from 1 in 11 in 2019.
The prevalence of Alzheimer's disease is directly correlated with age. As people live longer, the overall prevalence of the disease increases. According to statistics, the prevalence doubles approximately every five years after the age of 65, and about one-third of people aged 85 and older have Alzheimer's disease. This demographic trend amplifies the demand for effective treatments to manage the symptoms and slow the progression of the disease.
This demographic shift amplifies the need for effective interventions to address the cognitive decline associated with Alzheimer's disease within this growing population. Hence, growing geriatric population is expected to drive the market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Alzheimer’s Drugs Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Combination Therapies | Given the complex nature of Alzheimer's disease pathology, combination therapies are being explored to target multiple disease mechanisms simultaneously. This approach seeks to enhance treatment efficacy, potentially slow disease progression more effectively, and address the heterogeneity of Alzheimer's disease among different patient populations and driving the market growth. |
| Precision Medicine Approaches | The move towards precision medicine involves tailoring treatments based on individual genetic, and molecular characteristics. Personalized approaches aim to optimize therapeutic outcomes, minimize side effects, and enhance patient response to Alzheimer's drugs. Genetic testing and biomarker profiling are becoming increasingly integrated into clinical practice and research, expected to drive market demand. |
Alzheimer’s Drugs Market Segmentation
Market Breakup by Drug Class
- Memantine
- Cholinergic
- Combined Drug
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Alzheimer’s Drugs Market Share
Market Segmentation Based on Drug Class is Anticipated to Witness Substantial Growth
By drug class, the market is segmented into memantine, cholinergic, combined drugs, and others. The cholinergic segment is expected to dominate the market for its ability to enhance cholinergic neurotransmission. It works by inhibiting the breakdown of acetylcholine, a neurotransmitter essential for memory and cognitive functions. These drugs have demonstrated efficacy in improving cognitive symptoms, such as memory loss and cognitive impairment, in patients with Alzheimer's disease and thus driving the segmental growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Alzheimer’s Drugs Market Analysis by Region
Regionally, the market report offers an insight into the United States, EU-4 and the United Kingdom, Germany, France, Italy, Spain, United Kingdom, Japan, and India. The United States, having a robust healthcare infrastructure and a strong presence of prominent pharmaceutical companies, is estimated to hold a high market value in the forecast period. Increasing collaborations among the key market players boost research initiatives that are expected to fuel the region’s market share. Numerous clinical trials and research initiatives are often initiated and conducted in the country, leading to early access to novel therapies for patients leading to regional growth in the market.
Germany holds a significant Alzheimer’s drugs market value due to its significant and rapidly growing aging population and growing awareness of Alzheimer's disease. Increased awareness leads to earlier diagnosis, better management strategies, and greater demand for effective treatments.
Additionally, Japan is expected to witness substantial market growth due to ageing population, rising awareness and government initiatives.
Leading Players in the Alzheimer’s Drugs Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, fundings and investment analysis, and strategic initiatives such as partnerships, and collaborations analysis by the key players. The major companies in the market are as follows:
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd, commonly known as Roche, is a prominent pharmaceutical company that has been actively involved in the development and commercialization of drugs for Alzheimer's disease.
Novartis AG
Novartis AG, a global healthcare company headquartered in Switzerland, has been actively involved in Alzheimer's disease research and drug development.
Other key players in the market include Merck Sharp & Dohme Corp., Biogen Inc., AbbVie Inc., Eisai Co. Ltd, Johnson & Johnson Services, Inc., Daiichi Sankyo Company Limited, and Ono Pharmaceutical Co. Ltd. among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Alzheimer’s Drugs Market Report
- What was the Alzheimer’s drugs market value in 2023?
- What is the Alzheimer’s drugs market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on drug class?
- What is market segmentation based on route of administration?
- What is market segmentation based on distribution channel?
- What are the major factors aiding the Alzheimer’s drugs market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the growing geriatric population affect the market landscape?
- How does the clinical trials impact the market size?
- Who are the key players involved in the Alzheimer’s drugs market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Alzheimer’s Drugs Market Overview: 8 Major Market
3.1 Alzheimer’s Drugs Market Historical Value (2017-2023)
3.2 Alzheimer’s Drugs Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Alzheimer’s Drugs: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Alzheimer’s Drugs Market Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Alzheimer’s Drugs Market Landscape: 8 Major Market*
8.1 Alzheimer’s Drugs Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Alzheimer’s Drugs Market: Product Landscape
8.2.1 Analysis by Drug Class
8.2.2 Analysis by Route of Administration
9 Alzheimer’s Drugs Market Therapy Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Global Alzheimer’s Drugs: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Alzheimer’s Drugs Market Segmentation: 8 Major Markets
12.1 Alzheimer’s Drugs Market by Drug Class
12.1.1 Market Overview
12.1.2 Memantine
12.1.3 Cholinergic
12.1.4 Combined Drug
12.1.5 Others
12.2 Alzheimer’s Drugs Market by Route of Administration
12.2.1 Market Overview
12.2.2 Oral
12.2.3 Parenteral
12.3 Alzheimer’s Drugs Market by Distribution Channel
12.3.1 Market Overview
12.3.2 Retail Pharmacies
12.3.3 Hospital Pharmacies
12.3.4 Others
12.4 Alzheimer’s Drugs Market by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Alzheimer’s Drugs Market (2017-2032)
13.1 United States Alzheimer’s Drugs Market Historical Value (2017-2023)
13.2 United States Alzheimer’s Drugs Market Forecast Value (2024-2032)
13.3 United States Alzheimer’s Drugs Market by Drug Class
13.3.1 Market Overview
13.3.2 Memantine
13.3.3 Cholinergic
13.3.4 Combined Drug
13.3.5 Others
13.4 United States Alzheimer’s Drugs Market by Route of Administration
13.4.1 Market Overview
13.4.2 Oral
13.4.3 Parenteral
13.5 United States Alzheimer’s Drugs Market by Distribution Channel
13.5.1 Market Overview
13.5.2 Retail Pharmacies
13.5.3 Hospital Pharmacies
13.5.4 Others
14 EU-4 and United Kingdom Alzheimer’s Drugs Market (2017-2032)
14.1 EU-4 and United Kingdom Alzheimer’s Drugs Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Alzheimer’s Drugs Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Alzheimer’s Drugs Market by Drug Class
14.3.1 Market Overview
14.3.2 Memantine
14.3.3 Cholinergic
14.3.4 Combined Drug
14.3.5 Others
14.4 EU-4 and United Kingdom Alzheimer’s Drugs Market by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Parenteral
14.5 EU-4 and United Kingdom Alzheimer’s Drugs Market by Distribution Channel
14.5.1 Market Overview
14.5.2 Retail Pharmacies
14.5.3 Hospital Pharmacies
14.5.4 Others
15 Japan Alzheimer’s Drugs Market
15.1 Japan Alzheimer’s Drugs Market Historical Value (2017-2023)
15.2 Japan Alzheimer’s Drugs Market Forecast Value (2024-2032)
15.3 Japan Alzheimer’s Drugs Market by Drug Class
15.3.1 Market Overview
15.3.2 Memantine
15.3.3 Cholinergic
15.3.4 Combined Drug
15.3.5 Others
15.4 Japan Alzheimer’s Drugs Market by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Parenteral
15.5 Japan Alzheimer’s Drugs Market by Distribution Channel
15.5.1 Market Overview
15.5.2 Retail Pharmacies
15.5.3 Hospital Pharmacies
15.5.4 Others
16 India Alzheimer’s Drugs Market
16.1 India Alzheimer’s Drugs Market (2017-2032) Historical Value (2017-2023)
16.2 India Alzheimer’s Drugs Market (2017-2032) Forecast Value (2024-2032)
16.3 India Alzheimer’s Drugs Market by Drug Class
16.3.1 Market Overview
16.3.2 Memantine
16.3.3 Cholinergic
16.3.4 Combined Drug
16.3.5 Others
16.4 India Alzheimer’s Drugs Market by Route of Administration
16.4.1 Market Overview
16.4.2 Oral
16.4.3 Parenteral
16.5 India Alzheimer’s Drugs Market by Distribution Channel
16.5.1 Market Overview
16.5.2 Retail Pharmacies
16.5.3 Hospital Pharmacies
16.5.4 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grant Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Product
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 F. Hoffmann-La Roche Ltd
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Merck Sharp & Dohme Corp.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Biogen Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 AbbVie Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Eisai Co. Ltd
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Johnson & Johnson Services, Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Daiichi Sankyo Company Limited
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Ono Pharmaceutical Co. Ltd .
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Alzheimer’s Drugs Market – Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER